Last reviewed · How we verify
AOP2014
AOP2014 is a small molecule that targets the molecular target.
AOP2014 is a small molecule that targets the molecular target. Used for Phase 2 clinical trials for AOP2014 are currently ongoing for the treatment of various cancers..
At a glance
| Generic name | AOP2014 |
|---|---|
| Also known as | Pegylated-Proline-Interferon α-2b, P1101 |
| Sponsor | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS |
| Target | molecular target |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AOP2014 works by binding to the molecular target, which leads to a specific therapeutic effect. This mechanism is still being researched and more information is needed to fully understand its effects.
Approved indications
- Phase 2 clinical trials for AOP2014 are currently ongoing for the treatment of various cancers.
Common side effects
- Unknown
Key clinical trials
- Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia (PHASE2)
- P1101 in Treating Patients With Myelofibrosis (PHASE2)
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (PHASE2)
- ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (PHASE3)
- AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (PHASE3)
- Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PHASE3)
- Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |